JP2023551602A - Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット - Google Patents

Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット Download PDF

Info

Publication number
JP2023551602A
JP2023551602A JP2023553156A JP2023553156A JP2023551602A JP 2023551602 A JP2023551602 A JP 2023551602A JP 2023553156 A JP2023553156 A JP 2023553156A JP 2023553156 A JP2023553156 A JP 2023553156A JP 2023551602 A JP2023551602 A JP 2023551602A
Authority
JP
Japan
Prior art keywords
seq
tl1a
polymorphisms
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553156A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022103961A5 (https=
JP2023551602A5 (https=
Inventor
クルイデニア，ローランス
サブリッパー，マヤル
ディー． ワトキンス，ジェフリー
ティー． ディッカーソン，シンディー
ロハス，ラファエル
ライスマン，マシュー
マクニーリー，パトリシア
ビルズボロー，ジャニーン
ピー． マクガヴァン，ダーモット
リ，ダリン
Original Assignee
プロメテウス バイオサイエンシーズ，インク．
シーダーズ―シナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロメテウス バイオサイエンシーズ，インク．, シーダーズ―シナイ メディカル センター filed Critical プロメテウス バイオサイエンシーズ，インク．
Publication of JP2023551602A publication Critical patent/JP2023551602A/ja
Publication of JPWO2022103961A5 publication Critical patent/JPWO2022103961A5/ja
Publication of JP2023551602A5 publication Critical patent/JP2023551602A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023553156A 2020-11-13 2021-11-11 Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット Pending JP2023551602A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063113657P 2020-11-13 2020-11-13
US63/113,657 2020-11-13
US202163136153P 2021-01-11 2021-01-11
US63/136,153 2021-01-11
US202163147165P 2021-02-08 2021-02-08
US63/147,165 2021-02-08
US202163181074P 2021-04-28 2021-04-28
US63/181,074 2021-04-28
US202163226032P 2021-07-27 2021-07-27
US63/226,032 2021-07-27
PCT/US2021/058979 WO2022103961A1 (en) 2020-11-13 2021-11-11 Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Publications (3)

Publication Number Publication Date
JP2023551602A true JP2023551602A (ja) 2023-12-08
JPWO2022103961A5 JPWO2022103961A5 (https=) 2024-11-19
JP2023551602A5 JP2023551602A5 (https=) 2024-11-19

Family

ID=81602611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553156A Pending JP2023551602A (ja) 2020-11-13 2021-11-11 Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット

Country Status (14)

Country Link
US (1) US20230272098A1 (https=)
EP (1) EP4244251A4 (https=)
JP (1) JP2023551602A (https=)
KR (1) KR20230140553A (https=)
AU (1) AU2021377688A1 (https=)
BR (1) BR112023009172A2 (https=)
CA (1) CA3197828A1 (https=)
CL (1) CL2024001693A1 (https=)
CO (1) CO2023007607A2 (https=)
IL (1) IL302791A (https=)
MX (1) MX2023005688A (https=)
PH (1) PH12023500011A1 (https=)
TW (1) TW202233685A (https=)
WO (1) WO2022103961A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
WO2022232253A1 (en) * 2021-04-28 2022-11-03 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a
US20260066079A1 (en) * 2022-11-23 2026-03-05 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4646434A2 (en) * 2023-01-06 2025-11-12 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
EP4646443A1 (en) * 2023-01-06 2025-11-12 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and integrin inhibitors
KR20260013470A (ko) * 2023-05-17 2026-01-28 제넨테크, 인크. 항-tl1a 항체 치료 방법
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209995A2 (en) * 2018-04-25 2019-10-31 Precision Ibd, Inc. Optimized anti-tl1a antibodies
WO2019212899A1 (en) * 2018-04-30 2019-11-07 Cedars-Sinai Medical Center Methods and systems for selection and treatment of patients with inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0004928D0 (sv) * 2000-12-29 2000-12-29 Apbiotech Ab A method for the manufacturing of porous material
WO2002059264A2 (en) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Specific human antibodies for selective cancer therapy
WO2014186750A2 (en) * 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
MX388027B (es) * 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR102481305B1 (ko) * 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
US10626180B2 (en) * 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
JP2022533956A (ja) * 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209995A2 (en) * 2018-04-25 2019-10-31 Precision Ibd, Inc. Optimized anti-tl1a antibodies
WO2019212899A1 (en) * 2018-04-30 2019-11-07 Cedars-Sinai Medical Center Methods and systems for selection and treatment of patients with inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ENDO, K. ET AL.: "TL1A (TNFSF15) genotype affects the long-term therapeutic outcomes of anti-TNFα antibodies for Croh", JGH OPEN, vol. 4, no. 6, JPN6026003343, 1 August 2020 (2020-08-01), pages 1108 - 1113, ISSN: 0005785642 *

Also Published As

Publication number Publication date
CL2024001693A1 (es) 2024-11-29
US20230272098A1 (en) 2023-08-31
KR20230140553A (ko) 2023-10-06
EP4244251A4 (en) 2025-04-16
AU2021377688A1 (en) 2023-06-29
AU2021377688A9 (en) 2024-09-12
BR112023009172A2 (pt) 2023-10-03
PH12023500011A1 (en) 2024-03-11
WO2022103961A1 (en) 2022-05-19
EP4244251A1 (en) 2023-09-20
TW202233685A (zh) 2022-09-01
CA3197828A1 (en) 2022-05-19
IL302791A (en) 2023-07-01
MX2023005688A (es) 2023-07-18
CO2023007607A2 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
JP2023551602A (ja) Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
US20250382368A1 (en) Methods of treating a non-small cell lung cancer using an anti-pd-1 antibody
US20220290241A1 (en) Predicting extraintestinal manifestations of inflammatory bowel disease
US20240209103A1 (en) Patient selection methods and kits for therapies targeting tl1a
US20260066079A1 (en) Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN108350081A (zh) 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌
KR102644658B1 (ko) 모노클로날 항체 항-fgfr4
US20240101707A1 (en) A method of preventing, alleviating or treating a tumor
JP2024513692A (ja) グレムリン１アンタゴニストを使用して疾患を処置する方法
CN117279943A (zh) 通过靶向tl1a来治疗炎性疾病的方法、系统和试剂盒
KR20230024368A (ko) 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
WO2024249282A1 (en) Methods, systems, and kits for treatment of inflammatory diseases by targeting tl1a
RU2853818C1 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
RU2853818C9 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
KR20210102327A (ko) 암 치료를 위한 tim-3 항체 및 다른 체크포인트 억제제와의 조합

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260202